Illumina, Inc. vs Ishares Msci Thailand Etf — how do they compare? Illumina, Inc. trades at $191.46 (market cap $27.94B), while Ishares Msci Thailand Etf trades at $73.43. Which is the better fit depends on your goals.
| ILMN | THD | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $194.33 | $75.05 |
52-Week Low | $91.00 | $55.83 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
THD trades at $73.02, up 0.21% on the day, with a bullish technical outlook supported by moving averages and an upcoming dividend of $1.71 scheduled for June 2026. Recent news highlights its strong performance, with nearly 38% total returns over the past year, driven by exposure to AI hardware plays like Delta Electronics. The stock's momentum is reinforced by positive sentiment from financial media, though key financial ratios remain undisclosed in the provided data.
Outlook is cautiously optimistic due to technical strength and AI-driven growth potential, but risks include vulnerability to profit-taking and macroeconomic factors. Investors should monitor earnings reports for fundamental validation, as current data lacks detailed financial metrics. The stock faces competition and regional economic shifts, requiring careful assessment of future guidance.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →